Latest News and Press Releases

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be...

NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...

NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., April 19, 2022 ...

2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for...

NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...

JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce...

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...

JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions New offerings...

Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE...